ClinConnect ClinConnect Logo
Search / Trial NCT06821061

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Launched by BIONTECH SE · Feb 7, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how the flu vaccine and the COVID-19 vaccine work in healthy people, both when given alone and when mixed together. The goal is to understand how these vaccines act, which can help improve vaccination strategies in the future. The study is looking for healthy adults aged 18 and older to participate.

If you decide to join, you will receive one shot in your arm—either the flu vaccine, the COVID-19 vaccine, or a combination of both. You will need to visit the study site at least four times over about six months. To be eligible, you should be in good health and not have received any flu or COVID-19 vaccines in the past 150 days, nor any antiviral treatments for flu recently. If this sounds like something you’re interested in, please reach out for more details!

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Participants 18 years of age or older
  • Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgement of the investigator to be eligible for inclusion in the study
  • Exclusion criteria:
  • Vaccination with any investigational or licensed influenza vaccine within 150 days of enrollment
  • Vaccination with any investigational or licensed COVID 19 vaccine within 150 days of enrollment.
  • Receipt of antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1.
  • Refer to the study contact for further eligibility details

About Biontech Se

BioNTech SE is a leading biotechnology company headquartered in Mainz, Germany, specializing in the development of innovative immunotherapies for the treatment of cancer and infectious diseases. Founded in 2008, BioNTech leverages its proprietary mRNA technology platform to create personalized therapies and vaccines, with a strong focus on scientific excellence and clinical advancement. The company gained worldwide recognition for its groundbreaking COVID-19 vaccine, developed in collaboration with Pfizer, demonstrating its commitment to addressing urgent global health challenges. With a robust pipeline of candidates in various stages of development, BioNTech is dedicated to transforming the landscape of medicine through cutting-edge research and strategic partnerships.

Locations

Rochester, New York, United States

Walnut Creek, California, United States

Charlottesville, Virginia, United States

Honolulu, Hawaii, United States

Stockbridge, Georgia, United States

Milford, Connecticut, United States

Salt Lake City, Utah, United States

Anaheim, California, United States

Salt Lake City, Utah, United States

Miami, Florida, United States

San Diego, California, United States

Chesterfield, Missouri, United States

North Charleston, South Carolina, United States

Mesquite, Texas, United States

Riverside, California, United States

Nashville, Tennessee, United States

Tomball, Texas, United States

Hialeah, Florida, United States

Coral Gables, Florida, United States

North Las Vegas, Nevada, United States

Wilmington, North Carolina, United States

Philadelphia, Pennsylvania, United States

Columbus, Ohio, United States

Miami Lakes, Florida, United States

Houston, Texas, United States

Lake Forest, California, United States

East Syracuse, New York, United States

Brownsville, Texas, United States

Seattle, Washington, United States

Knoxville, Tennessee, United States

Patients applied

0 patients applied

Trial Officials

Pfizer CT.gov Call Center

Study Director

Pfizer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported